Navigation Links
Cancer stem cells recruit normal stem cells to fuel ovarian cancer, U-M study finds
Date:7/18/2011

ANN ARBOR, Mich. Researchers at the University of Michigan Comprehensive Cancer Center have found that a type of normal stem cell fuels ovarian cancer by encouraging cancer stem cells to grow.

Cancer stem cells are the small number of cells in a tumor that drive its growth and spread. Traditional cancer treatments do not kill these cells, which is why cancer treatments often fail.

In a study published online in the Journal of Clinical Investigation, researchers looked in ovarian tissue at the mesenchymal stem cells, which are normal cells found throughout the body. These cells can form different specialized cells such as fat, bone or cartilage.

Mesenchymal stem cells are known to be helpful with wound healing, which has many scientists conjecturing that they may help combat cancer. In this study, the researchers observed that mesenchymal stem cells in ovarian tumors were different than mesenchymal stem cells from healthy ovaries. And in fact, the mesenchymal stem cells in the ovarian tumors were fueling the cancer.

"Cancer is very good at tricking the mesenchymal stem cells into doing what the cancer likes. The cancer takes the cells hostage and uses them to promote the cancer's growth," says study author Ronald Buckanovich, M.D., Ph.D., assistant professor of internal medicine and of obstetrics and gynecology at the U-M Medical School.

The researchers used mouse models and human tissue samples of both normal ovaries and ovarian cancer, to look at what happened to the mesenchymal stem cells. They also noticed the cancer-associated mesenchymal stem cells increased tumor size, primarily by increasing the number of cancer stem cells.

At the same time, the researchers saw that a type of protein called BMP2 was prevalent in the cancer-associated mesenchymal stem cells. BMP2 is a so-called master regulatory protein, and is carefully regulated in normal cell function. The researchers found more than three times the amount of BMP in the cancer-associated mesenchymal stem cells than in the normal ones. When BMP was added to cancer cells, it led to an increase in cancer stem cells.

The researchers then used a known BMP inhibitor called Noggin, and found that Noggin blocked the mesenchymal stem cells from triggering this cancer stem cell growth.

"High doses of Noggin might not be tolerated in humans," Buckanovich says. "Our next step is to figure out how to target Noggin directly to the vascular niche where the mesenchymal stem cells and cancer stem cells live. This would allow us to make it safer to use Noggin as a potential treatment for ovarian cancer."

This research must continue in the laboratory before it can be advanced to clinical trials in patients. In the meantime, the U-M Comprehensive Cancer Center expects to open two new clinical trials within the next year testing other therapies aimed at attacking ovarian cancer stem cells. For information, contact the Cancer AnswerLine at 800-865-1125.

Ovarian cancer statistics: 21,880 Americans will be diagnosed with ovarian cancer this year and 13,850 will die from the disease, according to the American Cancer Society


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related biology news :

1. Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients
2. UT Southwestern research reveals that significantly more genetic mutations lead to colon cancer
3. Cancer gene therapy from camels
4. Cancer data not readily available for future research
5. UT faculty improving surgical outcomes for children, cancer patients
6. Study explains why men are at higher risk for stomach cancer
7. Stem cells restore cognitive abilities impaired by brain cancer treatment
8. PSA test for men could get a second life for breast cancer in women
9. Low dose naltrexone (LDN): Harnessing the bodys own chemistry to treat human ovarian cancer
10. GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients
11. AACR hosts Frontiers in Basic Cancer Research Conference in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer stem cells recruit normal stem cells to fuel ovarian cancer, U-M study finds 
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
Breaking Biology Technology: